| Name | Title | Contact Details |
|---|
PrinterPrezz`s mission is to bring more ideas for innovative medical devices to market faster, connecting medicine and manufacturing to become the first Medifacturing™ company in the world. By developing advanced medical devices using processes that combine expertise in 3D printing, orthopaedics, semiconductor and nanotechnologies, PrinterPrezz`s ultimate goal is to provide medical solutions that enable people to enjoy active lives longer. PrinterPrezz`s ecosystem aims to solve challenges for various parts of the medical innovation value chain by providing prototyping, development, and manufacturing services to create life-enhancing medical devices. Committed to ongoing compliance with ISO13485:2016 and all relevant regulatory requirements, PrinterPrezz provides customers with access to a variety of 3D printing machines, 3D manipulation software, and 3D scanners as well as advanced manufacturing processes, and surgeon education programs. Medical solutions created by PrinterPrezz are designed to enable more people to live happier and more gratifying lives.
OXiGENE is a biopharmaceutical company developing new and improved therapeutics that have the potential to deliver significant medical benefits to patients with cancer and serious medical conditions. Our primary focus is developing first-in-class anti-vascular drugs referred to as vascular disrupting agents (VDAs). Our lead compound in clinical development is fosbretabulin. VDAs are a new and highly differentiated class of anti-vascular drug that target existing tumor vasculature, leading to extensive tumor cell death. VDAs target the tumor vasculature rather than the tumor cells and therefore have broad potential therapeutic utility in cancer. Because VDAs act differently than anti-angiogenic drugs or cytotoxic chemotherapy drugs, VDAs are potentially complementary with anti-angiogenic drugs and chemotherapeutic agents. OXiGENE has ongoing VDA drug development programs and is committed to advancing the science of VDAs and their potential as innovative therapies to address unmet medical needs.
Silk Road Medical, Inc. is a medical device company located in Sunnyvale, California, that is focused on reducing the risk of stroke and its devastating impact. The company has pioneered a new approach for the treatment of carotid artery disease called TransCarotid Artery Revascularization (TCAR). TCAR is a clinically proven procedure combining surgical principles of neuroprotection with minimally invasive endovascular techniques to treat blockages in the carotid artery at risk of causing a stroke. The TransCarotid Artery Revascularization (TCAR) Procedure is a clinically proven procedure combining surgical principles of neuroprotection with minimally invasive endovascular techniques to treat blockages in the carotid artery at risk of causing a stroke. The ENROUTE® Transcarotid Neuroprotection and Stent System are the first and only products specifically designed and indicated for TCAR in high surgical risk patients that need carotid intervention.
Smith Philip B Dr. is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.